WO2001062964A2 - A genetic determinant for malignant melanoma - Google Patents
A genetic determinant for malignant melanoma Download PDFInfo
- Publication number
- WO2001062964A2 WO2001062964A2 PCT/GB2001/000753 GB0100753W WO0162964A2 WO 2001062964 A2 WO2001062964 A2 WO 2001062964A2 GB 0100753 W GB0100753 W GB 0100753W WO 0162964 A2 WO0162964 A2 WO 0162964A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- individual
- gene
- malignant melanoma
- genotype
- xrcc3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention is concerned with a genetic factor that may determine an individual's susceptibility to malignant melanoma.
- the invention concerns a novel association between a single nucleotide polymorphism in the DNA repair gene XRCC3 and the development of malignant melanoma.
- Malignant melanoma is a neoplastic lesion arising from epidermal melanocytes and is a highly invasive and aggressive cancer with a high mortality rate. Its incidence has rapidly increased over the past 30 years. The highest risk is associated with individuals with fair skin who are exposed to intense, intermittent periods of sunlight 1 . Extensive epidemiological and experimental data suggests that ultraviolet radiation is an important environmental carcinogen involved in the initiation and progression of skin cancer 2 . UV-radiation at short wavelengths induces damage in the form of cyclobutane pyrimidine dimers and pyrimidine (6-4) photoproducts . At longer wavelengths it causes single-stranded breaks, DNA- protein crosslinking and generates free-radicals which cause oxidative damage 3 . Cells respond to this damage through the activation of various DNA repair pathways.
- DNA repair systems are responsible for maintaining the integrity and of the genome in both somatic and germinal cells by minimising replication errors, deleterious rearrangements arising via aberrant recombination and by removing DNA damage 4,5 which might otherwise result in carcinogenesis .
- DNA repair has a critical role in protecting against mutations that can lead to cancer. Absence of incorrect repair can lead to the development of cancer through activation of oncogenes, inactivation of tumour-suppressor genes or loss of heterozygosity . Repair of damaged DNA involves many proteins performing functions directly on damaged DNA, as well as the interaction and interplay with proteins involved in regulation of DNA replication and progression through the cell cycle 6 .
- a given DNA repair defect may increase the rate of random mutations or may be specific for mutations associated with a particular carcinogen. In the case of malignant melanoma this would be ultra-violet radiation.
- UV-induced DNA damage and defective DNA repair mechanism is therefore likely to significantly increase the risk of developing skin cancer.
- DNA repair genes A number of polymorphisms in genes that encode DNA repair proteins have been described 18 . These genes, XRCC1, ERCC1, XPD, XPF and XRCC3, encode enzymes involved in three DNA repair pathways, known to be involved in the correction of UV-induced DNA damage. Many of the variants result in amino acid substitutions and exist at polymorphic allele frequencies (i.e. allele frequencies >0.05). Given the known relationship of DNA repair to cancer, polymorphic variants in the DNA repair enzymes have the potential to be population risk factors for cancer because of the large number of individuals affected.
- a method for determining whether an individual is likely to be susceptible to malignant melanoma which comprises screening the genome of said subject for the presence or absence of one or more polymorphic variants of the XRCC3 gene.
- the method of the invention preferably comprises screening the genome of the individual for one or more polymorphic variants of the XRCC3 gene which have previously been demonstrated to show statistically significant association with susceptibility to malignant melanoma, for example in a population-based genetic association study.
- the polymorphic variant will result in an amino acid substitution which may affect the function of the protein product encoded by the XRCC3 gene.
- the method of the invention comprises determining the genotype of the individual at position 18067 in exon 7 of the XRCC3 gene, wherein individuals having one or more T alleles at this position are scored as likely to be susceptible to malignant melanoma.
- a single nucleotide polymorphism at position 18067 in exon 7 of the XRCC3 gene has been shown to be associated with the development of malignant melanoma.
- the common allele is 18067 'C
- the variant allele associated with the development of malignant melanoma is 18067 ⁇ T' .
- the variant ⁇ T' allele occurs at a frequency of 0.38 18 and results in the non- conservative amino acid substitution T241M.
- the invention also contemplates screening for the presence of a protein product of the XRCC3 gene carrying this amino acid substitution.
- a method for determining whether an individual is likely to be susceptible to malignant melanoma which comprises determining the genotype of the said individual at two or more polymorphic loci selected from position 18067 in exon 7 of the XRCC3 gene, position 30028 in exon 11 of the XPF gene and position 2063 in the 5 ' UTR of the XPF gene, wherein individuals having three or more T alleles at these polymorphic loci are scored as likely to be susceptible to malignant melanoma.
- the method of the invention would involve determining the genotype of the individual at all three of the above-listed polymorphic loci.
- an individual's total genetic risk for developing UV- induced malignant melanoma may result from the presence of a combination of gene polymorphisms, an example of this being the observed additive effect of the XRCC3 exon 7 18067 T allele and the XPF exon 11 or XPF 5'UTR T alleles.
- the further polymorphisms associated with malignant melanoma need not necessarily all be single nucleotide polymorphisms but might include other types of polymorphic variation such as, for example, variable number tandem repeats. Moreover, the further polymorphisms need not necessarily occur in genes involved in DNA repair pathways but could be any polymorphic variation associated with melanoma. The further polymorphisms will preferably be ones for which a statistically significant association with malignant melanoma has been demonstrated, for example in a population-based association study.
- the panel might also include screens for polymorphic variants which are either in linkage disequilibrium with or in close physical proximity to a marker shown to be associated with melanoma but which have not themselves been shown to be associated with melanoma in a population-based study.
- linkage disequilibrium occurs between a marker polymorphism (e.g. a DNA polymorphism which is ⁇ silent' ) and a functional polymorphism (i.e. genetic variation which affects phenotype or which contributes to a genetically determined trait) if the marker is situated in close proximity to the functional polymorphism. Due to the close physical proximity, many generations may be required for alleles of the marker polymorphism and the functional polymorphism to be separated by recombination. As a result they will be present together on the same haplotype at higher frequency than expected, even in very distantly related people. As used herein the term "close physical proximity" means that the two markers/alleles in question are close enough for linkage disequilibrium to be likely to arise.
- the process of "determining the genotype" of an individual at a specific position of a given gene may advantageously comprise screening for the presence or absence in the genome of the subject of both the common allele and the variant allele or may comprise screening for the presence or absence of either individual allele, it generally being possible to draw conclusions about the genotype of an individual at a polymorphic locus having two alternative allelic forms just by screening for one or other of the specific alleles.
- the step of determining the genotype of an individual at a given polymorphic locus can be carried out using any suitable methodology known in the art and it is to be understood that the invention is in no way limited by the precise technique used to perform such genotyping.
- Known techniques for the scoring of single nucleotide polymorphisms include mass spectrometry, particularly matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS, ref 36) , single nucleotide primer extension 37,38 and DNA chips or microarrays 39 ' 40 .
- mass spectrometry particularly matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS, ref 36)
- single nucleotide primer extension 37,38 and DNA chips or microarrays 39 ' 40 .
- DNA chips or microarrays could enable simultaneous genotyping at many different polymorphic loci in a single individual or the simultaneous genotyping of a single polymorphic locus in multiple individuals.
- SNPs are commonly scored using PCR-based techniques, such as PCR-SSP using allele-specific primers (described by Bunce, 1995, ref 20) .
- This method generally involves performing DNA amplification reactions using genomic DNA as the template and two different primer pairs, the first primer pair comprising an allele-specific primer which under appropriate conditions is capable of hybridising selectively to the wild type allele and a non allele-specific primer which binds to a complementary sequence elsewhere within the gene in question, the second primer pair comprising an allele- specific primer which under appropriate conditions is capable of hybridising selectively to the variant allele and the same non allele-specific primer.
- a still further technique for scoring SNPs is the so-called PCR ELISA technique. SNPs may also be scored by DNA sequencing.
- genotyping can be carrying out by performing PCR using non-allele specific primers spanning the polymorphic site and digesting the resultant PCR product using the appropriate restriction enzyme (also known as PCR-RFLP) .
- Restriction fragment length polymorphisms including those resulting from the presence of a single nucleotide polymorphism, may also be scored by digesting genomic DNA with an appropriate enzyme then performing a Southern blot using a labelled probe corresponding to the polymorphic region (see Molecular Cloning: A Laboratory Manual, Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) .
- genotyping is generally carried out on genomic DNA prepared from a suitable tissue sample obtained from the subject under test. Most commonly, genomic DNA is prepared from a sample of whole blood, according to standard procedures which are well known in the art.
- the methods described herein provide simple and straightforward genetic screens which may be used to identify ⁇ at risk' individuals who may be more susceptible to the development of malignant melanoma by virtue of their genetic make-up.
- the ability to identify ⁇ at risk' individuals using these genetic screens may allow intervention with strategies aimed at reducing the impact of a high risk genotype- environment interaction in these individuals.
- the ⁇ at risk' individuals might be advised to reduce their exposure to environmental factors known to be associated with melanoma, for example by avoiding prolonged and/or repeated exposure to sunlight, or to take precautionary measures, such as the application of sunscreen.
- ⁇ At risk' individuals may also be primary candidates for new anti-melanoma therapies, such as topical application of DNA repair enzymes 34 and possibly gene therapy.
- the present invention provides a kit for use in determining the genotype of an individual at position 18067 in exon 7 of the XRCC3 gene, particularly in the context of any of the specific genetic screens mentioned herein, the kit comprising at least an oligonucleotide comprising 10 or more contiguous nucleotides from the human XRCC3 gene, including the polymorphic locus at position 18067.
- kits for use in performing simultaneous genotyping at two polymorphic loci selected from position 18067 in exon 7 of the XRCC3 gene, position 30028 in exon 11 of the XPF gene and position 2063 in the 5 ' UTR of the XPF gene comprising at least two oligonucleotides selected from: i) an oligonucleotide comprising 10 or more contiguous nucleotides from the human XRCC3 gene, including the polymorphic locus at position 18067; ii) an oligonucleotide comprising 10 or more contiguous nucleotides from the human XPF gene, including the polymorphic locus at position 30028; and iii) an oligonucleotide comprising 10 or more contiguous nucleotides from the human XPF gene, including the polymorphic locus at position 2063 in the 5' UTR.
- oligonucleotide molecules for inclusion into these kits are preferably from 10 to 50 nucleotides in length, even more preferably from 15-30 nucleotides in length. Skilled artisans will appreciate that the precise length of the oligonucleotide and positioning of the polymorphic nucleotide may vary depending upon the nature of the technique to be used to perform genotyping at the polymorphic locus. For example, PCR-SSP generally requires allele-specific primers in which the polymorphic nucleotide is positioned at the extreme 3 1 end (see list provided in the accompanying Example) , whereas techniques based on hybridisation might require allele-specific oligonucleotide probes having the polymorphic nucleotide positioned towards the middle of the probe.
- Oligonucleotides for inclusion into the kit may be synthesised using chemical synthesis techniques well known in the art.
- the oligonucleotides may be DNA, RNA or a synthetic nucleic acid and may be chemically or biochemically modified or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those skilled in the art. Possible modifications include, for example, the addition of isotopic or non-isotopic labels, substitution of one or more of the naturally occurring nucleotide bases with an analog, inter-nucleotide modifications such as uncharged linkages (e.g. methyl phosphonates, phosphoamidates, carbamates, etc.) or charged linkages (e.g.
- PNAs peptide nucleic acids
- the oligonucleotide molecules for inclusion into the kit are preferably single stranded and may correspond to the sense strand or the antisense strand of the relevant gene and to either allelic variant.
- the invention provides kits of primers for use in performing methods of the invention using PCR-SSP.
- Figure 1 is a graphical representation of the relationship between genotype frequencies for the XRCC3 exon 7 18067 C/T polymorphism and the risk of malignant melanoma.
- the black bars represent the cases from the malignant melanoma patient cohort, the white bars represent the controls.
- Figure 2 graphically illustrates the additive effect of the XRCC3 and XPF alleles for the total study group.
- the vertical bars represent the number of individuals carrying 0-4 risk alleles.
- the black bars represent the cases from the malignant melanoma patient cohort, the white bars represent the controls.
- Table 1 Genes selected for analysis with positions of single- nucleotide substitutions according to GenBank accession number (in brackets ) with resulting amino acid change .
- the patient cohort comprised of 125 individuals with histologically confirmed malignant melanoma. Patients were referred to the regional cancer centre if they had lesions or staging suggesting a high risk of relapse or if they had metastatic disease. All were
- the control population consisted of 211 caucasoid cadaveric renal transplant donors. The representative nature of this cohort of the UK population has been demonstrated in multiple HLA typing reports 19 .
- PCR-SSP polymerase-chain reaction technique
- Table 2 List of primers for PCR-SSP
- ERCC1 4 pos 19007-G 5' gCCAAATTCCCAgggCACg 16
- Phenotype, allele and genotype frequencies were calculated for the 10 DNA repair gene polymorphisms in the melanoma and control cohorts (Table 3) .
- Table 5 Analysis of XPF genotype showed that the TT genotype in position 2063 and the TT genotype in position 30028 were significantly associated with development of malignant melanoma. These associations did not remain significant after correcting for multiple comparisons.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001233933A AU2001233933A1 (en) | 2000-02-22 | 2001-02-22 | A genetic determinant for malignant melanoma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0004193.9 | 2000-02-22 | ||
GBGB0004193.9A GB0004193D0 (en) | 2000-02-22 | 2000-02-22 | A genetic determinant for malignant melanoma |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001062964A2 true WO2001062964A2 (en) | 2001-08-30 |
WO2001062964A3 WO2001062964A3 (en) | 2002-03-14 |
Family
ID=9886190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/000753 WO2001062964A2 (en) | 2000-02-22 | 2001-02-22 | A genetic determinant for malignant melanoma |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2001233933A1 (en) |
GB (1) | GB0004193D0 (en) |
WO (1) | WO2001062964A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005098034A1 (en) * | 2004-04-08 | 2005-10-20 | Hiltrud Brauch | Ercc2 polymorphisms |
EP1604009A2 (en) * | 2002-11-06 | 2005-12-14 | Sequenom, Inc. | Method for identifying risk of melanoma and treatments thereof |
WO2009047809A2 (en) * | 2007-10-12 | 2009-04-16 | Decode Genetics Ehf | Sequence variants for inferring human pigmentation patterns |
EP2520652A3 (en) * | 2004-04-09 | 2012-12-05 | Genecare Research Institute Co., Ltd | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes |
-
2000
- 2000-02-22 GB GBGB0004193.9A patent/GB0004193D0/en not_active Ceased
-
2001
- 2001-02-22 WO PCT/GB2001/000753 patent/WO2001062964A2/en active Application Filing
- 2001-02-22 AU AU2001233933A patent/AU2001233933A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
LIU NAN ET AL: "XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages." MOLECULAR CELL, vol. 1, no. 6, May 1998 (1998-05), pages 783-793, XP001000712 ISSN: 1097-2765 * |
PRICE E A ET AL: "Rare microsatellite polymorphisms in the DNA repair genes XRCC1, XRCC3 and XRCC5 associated with cancer in patients of varying radiosensitivity." SOMATIC CELL AND MOLECULAR GENETICS, vol. 23, no. 4, July 1997 (1997-07), pages 237-247, XP001000702 ISSN: 0740-7750 * |
SHEN M RICHARD ET AL: "Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans." CANCER RESEARCH, vol. 58, no. 4, 15 February 1998 (1998-02-15), pages 604-608, XP000999161 ISSN: 0008-5472 cited in the application * |
WINSEY S ET AL: "A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer." JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 115, no. 3, September 2000 (2000-09), page 538 XP001002656 Abstracts for the 30th European Society for Dermatological Research Annual Meeting;Berlin, Germany; September 21-23, 2000 ISSN: 0022-202X * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1604009A2 (en) * | 2002-11-06 | 2005-12-14 | Sequenom, Inc. | Method for identifying risk of melanoma and treatments thereof |
EP1604009A4 (en) * | 2002-11-06 | 2007-06-20 | Sequenom Inc | Method for identifying risk of melanoma and treatments thereof |
WO2005098034A1 (en) * | 2004-04-08 | 2005-10-20 | Hiltrud Brauch | Ercc2 polymorphisms |
EP2520652A3 (en) * | 2004-04-09 | 2012-12-05 | Genecare Research Institute Co., Ltd | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes |
US8470798B2 (en) | 2004-04-09 | 2013-06-25 | Genecare Research Institute Co., Ltd. | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
US8703930B2 (en) | 2004-04-09 | 2014-04-22 | Genecare Research Institute Co., Ltd. | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
WO2009047809A2 (en) * | 2007-10-12 | 2009-04-16 | Decode Genetics Ehf | Sequence variants for inferring human pigmentation patterns |
WO2009047809A3 (en) * | 2007-10-12 | 2009-08-13 | Decode Genetics Ehf | Sequence variants for inferring human pigmentation patterns |
Also Published As
Publication number | Publication date |
---|---|
GB0004193D0 (en) | 2000-04-12 |
WO2001062964A3 (en) | 2002-03-14 |
AU2001233933A1 (en) | 2001-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Morris et al. | Genetic and epigenetic regulation of human aging and longevity | |
Oka et al. | Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene | |
Coolen et al. | Impact of the genome on the epigenome is manifested in DNA methylation patterns of imprinted regions in monozygotic and dizygotic twins | |
Hishimoto et al. | Neurexin 3 polymorphisms are associated with alcohol dependence and altered expression of specific isoforms | |
Zschenker et al. | Association of single nucleotide polymorphisms in ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with clinical and cellular radiosensitivity | |
Solis et al. | Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria | |
Zhang et al. | Non-imprinted allele-specific DNA methylation on human autosomes | |
Torrezan et al. | Mutational spectrum of the APC and MUTYH genes and genotype–phenotype correlations in Brazilian FAP, AFAP, and MAP patients | |
Hirata et al. | Polymorphisms of DNA repair genes are risk factors for prostate cancer | |
US20050196794A1 (en) | Use of haplotypes and SNPs in lipid-relevant genes for the analysis and diagnosis of cardiovascular disease | |
Di Vinci et al. | HOXA7, 9, and 10 are methylation targets associated with aggressive behavior in meningiomas | |
Chang et al. | Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer | |
Barahmani et al. | Major histocompatibility complex class I chain-related gene A polymorphisms and extended haplotypes are associated with familial alopecia areata | |
Cheong et al. | Three new single nucleotide polymorphisms identified by a genome-wide association study in Korean patients with vitiligo | |
US20110300535A1 (en) | Method of identifying individuals at risk of thiopurine drug resistance and intolerance | |
Neishabury et al. | The influence of the BCL11A polymorphism on the phenotype of patients with beta thalassemia could be affected by the beta globin locus control region and/or the Xmn1-HBG2 genotypic background | |
US20030162207A1 (en) | Multi-gene tests with ROC plots for the assessment of risk for polygenic disorders | |
Chen et al. | Association of skin barrier genes within the PSORS4 locus is enriched in Singaporean Chinese with early-onset psoriasis | |
Kamboh et al. | A novel mutation in the apolipoprotein E gene (APOE* 4 Pittsburgh) is associated with the risk of late-onset Alzheimer's disease | |
Wlodarczyk et al. | XPD gene rs13181 polymorphism and DNA damage in human lymphocytes | |
Pulkkinen et al. | Detection of novel LAMC2 mutations in Herlitz junctional epidermolysis bullosa | |
KOSINIAK‐KAMYSZ et al. | Potential association of single nucleotide polymorphisms in pigmentation genes with the development of basal cell carcinoma | |
WO2001062964A2 (en) | A genetic determinant for malignant melanoma | |
Manderson et al. | Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer | |
Stachowiak et al. | Investigation of allele-specific expression of genes involved in adipogenesis and lipid metabolism suggests complex regulatory mechanisms of PPARGC1A expression in porcine fat tissues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |